Jenburkt Pharmaceuticals is currently trading at Rs. 450.00, up by 58.10 points or 14.83% from its previous closing of Rs. 391.90 on the BSE.
The scrip opened at Rs. 453.00 and has touched a high and low of Rs. 470.25 and Rs. 431.20 respectively. So far 16850 shares were traded on the counter.
The BSE group ‘X’ stock of face value Rs. 10 has touched a 52 week high of Rs. 550.00 on 29-Jul-2019 and a 52 week low of Rs. 243.20 on 19-Mar-2020.
Last one week high and low of the scrip stood at Rs. 470.25 and Rs. 383.00 respectively. The current market cap of the company is Rs. 179.86 crore.
The promoters holding in the company stood at 45.73%, while Institutions and Non-Institutions held 2.22% and 52.05% respectively.
Jenburkt Pharmaceuticals has launched antiviral drug Favipiravir (brand name Favivent) for the treatment of mild to moderate COVID-19 symptoms at a price of Rs 39 per tablet. This is not the first foray into timely, rapid innovation from the Jenburkt stable. This innovation-driven organisation was the first in the world to introduce Nervijen, Metmin-A, Powergesic, Infartin and a few more, across multiple therapeutic areas. The company’s R&D unit, approved by the Ministry of Science & Technology, Government of India, is their gateway to health through innovation.
Jenburkt is the second in India to introduce Favipiravir (brand name Favivent) for the treatment of COVID-19. Favivent is manufactured at a pharmaceutical plant which is compliant with US-FDA (U. S. Food and Drug Administration) and EDQM (The European Directorate for the Quality of Medicines & HealthCare) standards located in the state of Telangana, with the highest safety and manufacturing protocols in place. According to Jenburkt, the medication will be available in the form of 1 strip of 10 tablets.
Jenburkt Pharmaceuticals is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products.
